Roche Holding Ltd · SIX:RO
Roche — Jefferies Healthcare Conference 2024
21 slides from Roche's conference presentation, Jun 5, 2024
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Opening remarks
Opening remarks Bruno Eschli | Head of Investor Relations Jefferies Healthcare Conference , 5 June 2024
Slide 4: Group, Pharma, Diagnostics, Outlook
Group Pharma Diagnostics Outlook
Slide 5: Mid single digit sales growth expected for FY
Mid single digit sales growth expected for FY Strong growth of the base business, no material Covid-19 impact going forward Group base business sales growth Group sales growth excluding COVID related sales1 %CER %CER +15% +15% +10% +9% +10% +8% +7% +5% +5% +3% +3% +2% +1% +1% 0% +2% 0% -3% Covid-19
Slide 6: Extrapolated exchange rates
6 Extrapolated exchange rates Currency impact is improving significantly
Slide 7: Group, Pharma, Diagnostics, Outlook
Group Pharma Diagnostics Outlook
Slide 8: R&D Excellence: Pharma leading in multiple therapeutic areas
R&D Excellence: Pharma leading in multiple therapeutic areas Diversified portfolio of innovative medicines Number 1 in key therapeutic areas Pipeline #1 in Neurology and Hemophilia, 78 NMEs in clinical development leading in Ophthalmology and Oncology Portfolio Innovation Roche Sales per therapeutic
Slide 9: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term Two NME approvals expected for 2024: PiaSky (crovalimab) in PNH1 and inavolisib in HR+ breast cancer CHFm % of Pharma Sales3 7,000 50% 55% 6,000 5,000 42% 4,000 32% 3,000 2 2,000 1,000 0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Q1 202
Slide 10: Key Pharma growth drivers beyond 2025
Key Pharma growth drivers beyond 2025 Many opportunities with significant market potential NME Indication Newsflow Timing tiragolumab NSCLC Final Ph III data H2 2024 Oncology / inavolisib BC US/EU filing 2024 Hematology divarasib NSCLC Ph I/II readout 2024/25 giredestrant BC Ph III readout 2025 Elev
Slide 11: R&D Excellence – Our 2030 goals
R&D Excellence – Our 2030 goals Ambition to have the industry-leading R&D engine Increase Phase 0 Increase average peak year Increase Phase 3 initiations / year1: sales of pipeline assets: success rate: + 50% + 50% + 22%p. Success Volume Value rate Effectiveness R&D Excellence Costs Cycle time Effic
Slide 12: Pharma pipeline evolution in the last three quarters
Pharma pipeline evolution in the last three quarters Portfolio shaping ongoing: Focus on high-impact projects led to termination of 20% of total NMEs since Q2 23 NME changes since Q2 23 siRNA targeting AGT in hypertension NMEs added +13 8 -8 -3 Oncology / Hematology +5 (2) 81 4 1 Immunology +2 (1) -
Slide 13: Group, Pharma, Diagnostics, Outlook
Group Pharma Diagnostics Outlook
Slide 14: R&D Excellence: Diagnostics is leading in innovation
R&D Excellence: Diagnostics is leading in innovation We set the standard in the diagnostics industry Number 1 in Diagnostics Innovation #1 with high single-digit growth 14 FDA Breakthrough Device over past years1 Designations since 20183 FDA-approvals Pipeline New FDA-Approvals (PMA/BLA) (Roche Diag
Slide 15: Diagnostics contributing to the overall Group success
Diagnostics contributing to the overall Group success COVID-19 testing sales washed out and integration of FMI and Diabetes Care Diagnostics sales and margin development 2019-23 Realizing synergies in Diagnostics and the Group Core OP Shift of FMI from Pharma to Diagnostics Division CHF bn +7% CAGR
Slide 16: Important launches in Diagnostics from 2024 onwards
Important launches in Diagnostics from 2024 onwards Diagnostics to deliver mid to high single digit growth in coming years Continuous glucose Next generation Core & Molecular Lab Mass spectrometry monitoring (CGM) sequencing (NGS) • Menu expansion driving growth, • First fully integrated and • Subcu
Slide 17: Group, Pharma, Diagnostics, Outlook
Group Pharma Diagnostics Outlook
Slide 18: 2024 outlook confirmed
2024 outlook confirmed Group sales growth1 Mid single digit sales growth Broadly in line with sales growth Core EPS growth1 excl. impact from resolution of tax disputes in 2023 Dividend outlook Further increase dividend in Swiss francs 1At Constant Exchange Rates (CER) 18
Slide 19: Key growth drivers beyond 2025
Key growth drivers beyond 2025 Many opportunities with significant market potential in both divisions Pharmaceuticals Diagnostics NME Indication Newsflow Timing Product Description Launch tiragolumab NSCLC Final Ph III data H2 2024 Total solution for clinical mass i601 mass spec 2024 spectrometry an
Slide 20: Upcoming Roche IR events 2024
Upcoming Roche IR events 2024 Additional events driven by readouts Diagnostics Day Oncology/ASCO Hematology / EHA Ophthalmology/ASRS Pharma Day May 22 May 31 June 16 Jul 23 Sep 30 • Deep-dive into the • Oncology solid tumors • Ph III (STARGLO) results • Ophthalmology • Update on Group & current prod
Slide 21: Doing now what patients need next
Doing now what patients need next